Two new compounds could reveal hidden drivers of Alzheimer’s disease
Researchers have developed new tool compounds to selectively inhibit the TAOK-1 protein, which is linked to Alzheimer's disease. This advancement provides scientists with a more precise method to study the biological drivers of the condition, potentially paving the way for future drug development.
Why it matters
Understanding the specific biological mechanisms of Alzheimer's is a critical hurdle in moving from symptom management to developing effective, disease-modifying cures.
Alzheimer's disease is the leading cause of dementia and currently affects more than seven million people in the United States. Some available treatments can slow the disease, but most primarily address symptoms, and none can cure it.
"Alzheimer's is a condition that remains recalcitrant to the scientific community's attempts at developing a cure or preventative treatment," said Daniel Schultz, a former postdoctoral fellow in the Vanderbilt University Warren Center for Neuroscience Drug Discovery.
One major obstacle to developing better therapies is that researchers still do not fully understand the biology behind Alzheimer's disease. The same problem affects research into many other neurological diseases and neurodevelopmental disorders.
Scientists have identified genes and proteins that may contribute to these conditions, but studying them can be extremely difficult when researchers lack a reliable way to change how those biological targets behave.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in